Company research / ENGN

enGene Therapeutics Inc. (ENGN)

Build a valuation ↗↓ Download CSV

CIK 0001980845

Key ratios (year ended 2025-10-31)

-69.9%

Return on year-end equity

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: 8-K · 2026-08-11

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. A dash means a matching observation is unavailable.

Period ended	2025-10-31	2024-10-31	2023-10-31	2022-10-31	2021-10-31
Operating Income	-$123.17M	-$62.30M	-$26.06M	-$19.43M	—
Net Income	-$117.30M	-$55.14M	-$99.92M	-$24.46M	—
EPS (Diluted)	$2.29	$1.46	$151.22	$44.30	—
Total Assets	$221.47M	$311.17M	$86.96M	$23.91M	—
Total Liabilities	$53.76M	$38.56M	$14.47M	$47.41M	—
Shareholders' Equity	$167.71M	$272.61M	$72.49M	-$76.61M	-$53.44M
Cash & Equivalents	$50.15M	$173.00M	$81.52M	$20.43M	—
Operating Cash Flow	-$99.24M	-$48.28M	-$24.74M	-$17.59M	—
Capital Expenditures	$1.49M	$925.0K	$318.0K	$153.0K	—
Shares Outstanding	52.02M	50.98M	23.20M	665.8K	—
Dividends Per Share	$0.00	$0.00	$0.00	—	—
Weighted Average Diluted Shares	51.12M	37.78M	692.6K	655.2K	—
EPS (Basic)	$2.29	$1.46	$151.22	$44.30	—